Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Xavier B. Pivot, Rubi K. Li, Eva S. Thomas, Hyun Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Fernando Hurtado de Mendoza, Pralay Mukhopadyay, Henri H. Roché

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.

Original languageEnglish
Pages (from-to)2940-2946
Number of pages7
JournalEuropean Journal of Cancer
Volume45
Issue number17
DOIs
Publication statusPublished - 2009 Nov 1

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Therapeutics
Taxoids
Phase III Clinical Trials
Aromatase Inhibitors
Tamoxifen
Drug Resistance
human ERBB2 protein
ixabepilone
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Pivot, Xavier B. ; Li, Rubi K. ; Thomas, Eva S. ; Chung, Hyun Cheol ; Fein, Luis E. ; Chan, Valorie F. ; Jassem, Jacek ; Mendoza, Fernando Hurtado de ; Mukhopadyay, Pralay ; Roché, Henri H. / Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. In: European Journal of Cancer. 2009 ; Vol. 45, No. 17. pp. 2940-2946.
@article{b40805f2d330458ea5a44c08313b0a6e,
title = "Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer",
abstract = "Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.",
author = "Pivot, {Xavier B.} and Li, {Rubi K.} and Thomas, {Eva S.} and Chung, {Hyun Cheol} and Fein, {Luis E.} and Chan, {Valorie F.} and Jacek Jassem and Mendoza, {Fernando Hurtado de} and Pralay Mukhopadyay and Roch{\'e}, {Henri H.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1016/j.ejca.2009.07.015",
language = "English",
volume = "45",
pages = "2940--2946",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "17",

}

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. / Pivot, Xavier B.; Li, Rubi K.; Thomas, Eva S.; Chung, Hyun Cheol; Fein, Luis E.; Chan, Valorie F.; Jassem, Jacek; Mendoza, Fernando Hurtado de; Mukhopadyay, Pralay; Roché, Henri H.

In: European Journal of Cancer, Vol. 45, No. 17, 01.11.2009, p. 2940-2946.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

AU - Pivot, Xavier B.

AU - Li, Rubi K.

AU - Thomas, Eva S.

AU - Chung, Hyun Cheol

AU - Fein, Luis E.

AU - Chan, Valorie F.

AU - Jassem, Jacek

AU - Mendoza, Fernando Hurtado de

AU - Mukhopadyay, Pralay

AU - Roché, Henri H.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.

AB - Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.

UR - http://www.scopus.com/inward/record.url?scp=70449096190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449096190&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2009.07.015

DO - 10.1016/j.ejca.2009.07.015

M3 - Article

C2 - 19683429

AN - SCOPUS:70449096190

VL - 45

SP - 2940

EP - 2946

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 17

ER -